1292280-44-4Relevant academic research and scientific papers
Preparation and Bioactivity of Iridium(III) Phenanthroline Complexes with Halide Ions and Pyridine Leaving Groups
Liu, Xicheng,Shao, Mingxiao,Liang, Congcong,Guo, Jinghang,Wang, Guangxuan,Yuan, Xiang-Ai,Jing, Zhihong,Tian, Laijin,Liu, Zhe
, p. 557 - 564 (2021)
A series of half-sandwich structural iridium(III) phenanthroline (Phen) complexes with halide ions (Cl?, Br?, I?) and pyridine leaving groups ([(η5-CpX)Ir(Phen)Z](PF6)n, Cpx: electron-rich cyclopentadienyl group, Z: leaving group) have been prepared. Target complexes, especially the Cpxbiph (biphenyl-substituted cyclopentadienyl)-based one, showed favourable anticancer activity against human lung cancer (A549) cells; the best one (Ir8) was almost five times that of cisplatin under the same conditions. Compared with complexes involving halide ion leaving groups, the pyridine-based one did not display hydrolysis but effectively caused lysosomal damage, leading to accumulation in the cytosol, inducing an increase in the level of intracellular reactive oxygen species and apoptosis; this indicated an anticancer mechanism of oxidation. Additionally, these complexes could bind to serum albumin through a static quenching mechanism. The data highlight the potential value of half-sandwich iridium(III) phenanthroline complexes as anticancer drugs.
NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS
-
Paragraph 0119; 0123, (2013/03/28)
The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS
-
Page/Page column 22, (2011/12/14)
The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
